In this episode (19.08 minutes), Medicom’s correspondent covers 6 presentations from the Annual Meeting of the American Heart Association (AHA 2022), held in Chicago (IL, US) from 5-7 November 2022.
The topics discussed are:
- Torsemide not superior to furosemide in hospitalized HF patients
Comparing treatment with loop diuretics furosemide and torsemide in hospitalised patients with heart failure (HF) did not ascertain an advantage in the clinical outcome of all-cause mortality in the phase 3 TRANSFORM-HF trial. Furthermore, no difference was found in total hospitalisations at 12 months. - Empagliflozin beneficial for kidney disease progression and CV outcomes
Empagliflozin significantly reduced the risk of the composite outcome of progression of kidney disease or death from cardiovascular (CV) causes by 28% in the phase 3 EMPA-KIDNEY trial. The results also showed a 14% decrease in hospitalisation due to any cause. - Olpasiran leads to dramatic reductions in Lp(a) concentrations
Olpasiran, a small interfering RNA molecule, successfully reduced lipoprotein levels by >90% in patients with atherosclerotic cardiovascular disease in the phase 2 OCEAN(a)-DOSE trial. The agent was well tolerated with only mild increases in injection site reactions. - Grafting with radial artery: an underrated option in CABG surgery?
Coronary artery bypass graft (CABG) procedures using the radial artery as a conduit for the second most important target vessel had superior clinical outcomes after 15 years. Compared with the free right internal thoracic artery (RITA) and a saphenous vein graft (SVG), the use of the radial artery entailed a 26% and a 29% reduction, respectively, in major adverse cardiac events (MACE). - Dietary supplements futile in lowering LDL-C
Rosuvastatin at a low dose clearly outperformed placebo and various dietary supplements in decreasing LDL-cholesterol (LDL-C), total cholesterol and triglycerides. Furthermore, no supplement was superior to placebo in lowering LDL-C. - The endothelin system: a new target for resistant high blood pressure
Two different doses of aprocitentan were superior to placebo in patients with insufficiently treated hypertension despite intensive therapy. After 4 weeks, the systolic BP was significantly more decreased and this effect was maintained during the open label study part of 32 weeks.
Enjoy listening!
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Letter from the Editor Next Article
No increased cancer risk in patients with rheumatic diseases and prior malignancy treated with novel therapies »
« Letter from the Editor Next Article
No increased cancer risk in patients with rheumatic diseases and prior malignancy treated with novel therapies »
Table of Contents: AHA 2022
Featured articles
What Is New in Heart Failure
Torsemide not superior to furosemide after hospitalisation for heart failure
IRONMAN failed primary endpoint but shows potential long-term benefits of iron repletion in HF patients
Up-titration of HF therapies following HF discharge saves lives
Hypertension: Novel Developments
The endothelin system: a new target for resistant high blood pressure
Can renal denervation lower BP on top of antihypertensive drugs?
Quadruple, ultra-low-dose treatment did not meet primary endpoint in hypertension
Mindfulness programme contributes to office blood pressure lowering
Interventional Cardiology in 2022
Grafting with the radial vein: an underrated option in CABG surgery?
Extracorporeal membrane oxygenation not superior to conservative therapy in cardiogenic shock
Surgery with adequate saphenous vein partly better than endovascular treatment in CLTI
Arrhythmia – State of the Art
First-line ablation limits progression to persistent AF
Doubling the dose of self-administered etripamil terminates PSVT
Novel Developments in Primary and Secondary Prevention
Grafting with the radial vein: an underrated option in CABG surgery?
Digitally delivered cognitive behavioural therapy successful in type 2 diabetes
Empagliflozin reduces risk of kidney disease progression and CV events in patients with CKD
RESPECT-EPA misses primary endpoint but hints towards improvements in CV outcomes by EPA
Pemafibrate fails to reduce cardiovascular events in diabetes but may benefit the liver
Dietary supplements not effective in lowering LDL-C, use of low-dose statins encouraged
No sex differences in lipid-lowering effect and treatment benefit of PCSK9 inhibitors
COVID-19 and the Heart
‘No’ to routine use of rivaroxaban in outpatients with COVID-19
COVID-19 pandemic: Older adults and those affected by the delta variant experienced increased cardiovascular morbidity and mortality
COVID-19 mRNA vaccination does not amplify risk of cardiovascular hospitalisation
Best of the Posters
Higher LDL-cholesterol levels linked to higher CVD mortality risk in the elderly
AF: Moderate alcohol intake possibly associated with a reduced mortality risk
Periodontitis: An independent risk factor for AF
Related Articles
January 11, 2023
Doubling the dose of self-administered etripamil terminates PSVT
January 11, 2023
Can renal denervation lower BP on top of antihypertensive drugs?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com